Ocular Therapeutix, Inc.OCULNASDAQ
Loading
Year-over-year net income growth rate
3Y CAGR
-42.3%/yr
vs +14.2%/yr prior
Acceleration
-56.5pp
Decelerating
Percentile
P67
Within normal range
vs 3Y Ago
0.2x
Contraction
Streak
4 qtr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| Q4 2025 | 6.86% |
| Q3 2025 | -2.37% |
| Q2 2025 | -5.87% |
| Q1 2025 | -32.37% |
| Q4 2024 | -32.60% |
| Q3 2024 | 16.64% |
| Q2 2024 | 32.49% |
| Q1 2024 | -121.93% |
| Q4 2023 | -5562.79% |
| Q3 2023 | 97.51% |
| Q2 2023 | 31.78% |
| Q1 2023 | -95.07% |
| Q4 2022 | 35.74% |
| Q3 2022 | -28.89% |
| Q2 2022 | -49.63% |
| Q1 2022 | -225.77% |
| Q4 2021 | -244.90% |
| Q3 2021 | 131.33% |
| Q2 2021 | -371.74% |
| Q1 2021 | 103.65% |
| Q4 2020 | -616.78% |
| Q3 2020 | 67.34% |
| Q2 2020 | -69.99% |
| Q1 2020 | 17.32% |
| Q4 2019 | -38.55% |
| Q3 2019 | 23.21% |
| Q2 2019 | -42.80% |
| Q1 2019 | 1.58% |
| Q4 2018 | -15.92% |
| Q3 2018 | -8.74% |
| Q2 2018 | -0.28% |
| Q1 2018 | -5.06% |
| Q4 2017 | 15.83% |
| Q3 2017 | 16.73% |
| Q2 2017 | -16.67% |
| Q1 2017 | -24.96% |
| Q4 2016 | -33.62% |
| Q3 2016 | 16.16% |
| Q2 2016 | -5.58% |
| Q1 2016 | -1.91% |